Search

U.S. Bankruptcy Judge Shelley C. Chapman is overseeing the mediation and delivered the update in a written report Monday evening. The family and a handful of state attorneys general that have been opposing Purdue's opioid settlement are nearing a deal that would provide a "substantial" additional contribution on top of the $4.325 billion the company's owners already pledged, according to the court documents. (Bloomberg) -- Members of the billionaire Sackler family that own Purdue Pharma LP are close to a deal to increase their contribution to the OxyContin maker's sweeping opioid settlement, court papers show. [Extracted from the article]

The family and a handful of state attorneys general who have been opposing Purdue's opioid settlement are nearing a deal that would provide a "substantial" additional contribution on top of the $4.325 billion the company's owners already pledged, according to the court documents. Do or "Dire" In a hearing Tuesday, Purdue's bankruptcy judge, Robert Drain, said he would extend the mediation to Feb. 7. (Bloomberg) -- Members of the billionaire Sackler family that own Purdue Pharma LP are close to a deal that would increase their contribution to the OxyContin maker's sweeping opioid settlement, court papers show. [Extracted from the article]

The family and a handful of state attorneys general that have been opposing Purdue's opioid settlement are nearing a deal that would provide a "substantial" additional contribution on top of the $4.325 billion the company's owners already pledged, according to the court documents. (Bloomberg) -- Members of the billionaire Sackler family that own Purdue Pharma LP are close to a deal to increase their contribution to the OxyContin maker's sweeping opioid settlement, court papers show. She found that its bankruptcy judge doesn't have the authority to give members of the Sackler family the legal protection the deal called for, dealing a startling blow to a long-controversial aspect of bankruptcy law. [Extracted from the article]

The article offers a look into the obscurity of mifepristone, an abortion pill developed by French pharmaceutical firm Roussel Uclaf, since its approval by the U.S. Food and Drug Administration (FDA) in 2000. It attributes the obscurity of the pill to regulatory restrictions known as risk evaluation and mitigation strategy (REMS) that included prescribing. It explores implication of the U.S. Supreme Court's possible overturn of the Roe v. Wade abortion rights ruling on the sale of mifepristone.

During a virtual court hearing on the proposal Thursday, U.S. Bankruptcy Judge John Dorsey asked how the legal protections would affect creditors who may want to keep suing Mallinckrodt. (Bloomberg) -- The judge overseeing the reorganization of opioid maker Mallinckrodt Plc questioned the fairness of a plan to protect executives and others from future lawsuits, echoing the dispute that upended Purdue Pharma's effort to settle its own highly charged opioid bankruptcy case. [Extracted from the article]

During a virtual court hearing on the proposal Thursday, U.S. Bankruptcy Judge John Dorsey asked how the legal protections would affect creditors who may want to keep suing Mallinckrodt. Mallinckrodt disputes those accusations, but filed bankruptcy in part to find a way to resolve the claims, company attorney Christopher Harris said in court on Thursday. (Bloomberg) -- The judge overseeing the reorganization of opioid maker Mallinckrodt Plc questioned the fairness of a plan to protect company executives and others from future lawsuits. [Extracted from the article]